Understanding how genetic background affects rare tumors and their treatment responses
Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid models
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-10922102
This study is looking at how your genetic background might affect the way rare tumors called pheochromocytomas and paragangliomas behave and respond to treatment, especially for patients from underrepresented racial and ethnic groups, to help find better ways to detect and treat these tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-10922102 on ClinicalTrials.gov |
What this research studies
This research investigates the role of genetic ancestry in the biology and treatment responses of rare neuroendocrine tumors called pheochromocytomas and paragangliomas. By creating patient-derived organoid models, the study aims to identify how genetic factors and social determinants influence tumor behavior and drug effectiveness. The research focuses on underrepresented racial and ethnic minority patients, aiming to improve early detection and treatment options for aggressive forms of these tumors. Patients will be recruited to provide samples that will help develop these innovative models.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals from underrepresented racial and ethnic backgrounds diagnosed with pheochromocytomas or paragangliomas.
Not a fit: Patients with common tumors or those not from the targeted racial and ethnic groups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients with rare tumors.
How similar studies have performed: Previous research has shown promise in using patient-derived organoid models to study cancer, indicating potential for success in this novel approach.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAHIA, PATRICIA LEAL — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: DAHIA, PATRICIA LEAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.